WO2000042216A3 - Genetic predisposition to abnormal calcification conditions - Google Patents

Genetic predisposition to abnormal calcification conditions Download PDF

Info

Publication number
WO2000042216A3
WO2000042216A3 PCT/EP2000/000319 EP0000319W WO0042216A3 WO 2000042216 A3 WO2000042216 A3 WO 2000042216A3 EP 0000319 W EP0000319 W EP 0000319W WO 0042216 A3 WO0042216 A3 WO 0042216A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
genetic predisposition
abnormal calcification
calcification conditions
conditions
Prior art date
Application number
PCT/EP2000/000319
Other languages
French (fr)
Other versions
WO2000042216A2 (en
Inventor
Philip Kusk
Original Assignee
Osteometer Biotech As
Philip Kusk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9901037.3A external-priority patent/GB9901037D0/en
Priority claimed from GBGB9912585.8A external-priority patent/GB9912585D0/en
Application filed by Osteometer Biotech As, Philip Kusk filed Critical Osteometer Biotech As
Priority to JP2000593773A priority Critical patent/JP2005517379A/en
Priority to EP00909076A priority patent/EP1144686A2/en
Priority to AU31492/00A priority patent/AU3149200A/en
Publication of WO2000042216A2 publication Critical patent/WO2000042216A2/en
Publication of WO2000042216A3 publication Critical patent/WO2000042216A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Methods of assessing an individual's predisposition to abnormal calcification conditions such as osteoporosis by determining the genotype of a promoter for the bone sialoprotein gene, the matrix gla protein gene, the osteoponting gene or the osteoprotegerin gene individually or in any combination. Specific allelic variations for each promoter are described.
PCT/EP2000/000319 1999-01-18 2000-01-17 Genetic predisposition to abnormal calcification conditions WO2000042216A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000593773A JP2005517379A (en) 1999-01-18 2000-01-17 Genetic predisposition
EP00909076A EP1144686A2 (en) 1999-01-18 2000-01-17 Genetic predisposition to abnormal calcification conditions
AU31492/00A AU3149200A (en) 1999-01-18 2000-01-17 Genetic predisposition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9901037.3A GB9901037D0 (en) 1999-01-18 1999-01-18 Genetic predisposition
GB9901037.3 1999-01-18
GB9912585.8 1999-05-28
GBGB9912585.8A GB9912585D0 (en) 1999-05-28 1999-05-28 Genetic predisposition

Publications (2)

Publication Number Publication Date
WO2000042216A2 WO2000042216A2 (en) 2000-07-20
WO2000042216A3 true WO2000042216A3 (en) 2000-11-02

Family

ID=26314996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000319 WO2000042216A2 (en) 1999-01-18 2000-01-17 Genetic predisposition to abnormal calcification conditions

Country Status (4)

Country Link
EP (1) EP1144686A2 (en)
JP (1) JP2005517379A (en)
AU (1) AU3149200A (en)
WO (1) WO2000042216A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7720600A (en) * 1999-09-27 2001-04-30 Eli Lilly And Company Osteoprotegerin regulatory region
EP2132568B1 (en) 2007-03-30 2013-05-29 Chu Sainte-justine Method of determining risk of scoliosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705842A2 (en) * 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta
WO1997003555A1 (en) * 1995-07-17 1997-02-06 Hoechst Pharmaceuticals & Chemicals K.K. Transgenic animal model of osteopenia
EP0784093A1 (en) * 1995-12-22 1997-07-16 Amgen Inc. Osteoprotegerin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705842A2 (en) * 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta
WO1997003555A1 (en) * 1995-07-17 1997-02-06 Hoechst Pharmaceuticals & Chemicals K.K. Transgenic animal model of osteopenia
EP0784093A1 (en) * 1995-12-22 1997-07-16 Amgen Inc. Osteoprotegerin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRANDSTROM, H. (1) ET AL: "Polymorphism in the promoter region of the human gene for osteoprotegerin: Correlation with bone mineral density.", JOURNAL OF BONE AND MINERAL RESEARCH, (SEPT., 1999) VOL. 14, NO. SUPPL. 1 PP. S334. MEETING INFO.: TWENTY-FIRST ANNUAL MEETING OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH ST. LOUIS, MISSOURI, USA SEPTEMBER 30-OCTOBER 4 1999 AMERICAN SOCIETY, XP000915449 *
BUCAY N ET AL: "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification", GENES AND DEVELOPMENT,US,COLD SPRING HARBOR LABORATORY PRESS, NEW YORK, vol. 12, no. 9, 1 May 1998 (1998-05-01), pages 1260 - 1268, XP002090118, ISSN: 0890-9369 *
KIM R H ET AL: "Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene.", BIOCHEMICAL JOURNAL, (1996 AUG 15) 318 ( PT 1) 219-26., XP002142619 *
LUO: "Spontaneous calcification of arteries and cartilage in mice lacking GLA protein", NATURE, vol. 386, 6 March 1996 (1996-03-06), pages 78 - 81, XP002142620 *
MUNROE P B ET AL: "Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome.", NATURE GENETICS, (1999 JAN) 21 (1) 142-4., XP000929109 *

Also Published As

Publication number Publication date
EP1144686A2 (en) 2001-10-17
JP2005517379A (en) 2005-06-16
AU3149200A (en) 2000-08-01
WO2000042216A2 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
WO2002018638A3 (en) Detection of cyp2d6 polymorphisms
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof
AU2299999A (en) Dnas or genes participating in parkinson's disease
WO2002086156A3 (en) New polynucleotides and polypeptides of the ifn$g(a)-17 gene
WO2000022122A3 (en) Genes, proteins and biallelic markers related to central nervous system disease
WO2000042216A3 (en) Genetic predisposition to abnormal calcification conditions
NZ332702A (en) Diagnostic method and apparatus for detecting a predisposition to certain disease states, especially osteoporosis, based on polymorphism in an IL-6 gene
WO2001023410A3 (en) Drug target isogenes: polymorphisms in the interleukin 13 gene
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers
WO2003000896A3 (en) POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE
WO2002101048A3 (en) NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE
AU6091199A (en) Method for determining susceptibility to heart disease by screening polymorphisms in the vitamin d receptor gene
WO2004090164A3 (en) Method for determining soil condition
WO2003079747A3 (en) An isolated polynucleotide associated with type ii diabetes mellitus and methods of use thereof
AU2000263446A1 (en) Drug target isogenes: polymorphisms in the interleukin 4 receptor alpha gene
WO2003018835A3 (en) Method for rapid detection of haplotypes
AU6091099A (en) Method for determining susceptibility to bone damage by screening polymorphisms in the vitamin d receptor gene
WO2001077380A3 (en) Method for predicting predisposition to a disease associated with mutations in a rpgr gene
WO2001058914A3 (en) Haplotypes of the interleukin 15 gene
WO2001011010A3 (en) Drug target isogenes: polymorphisms in the immunoglobulin e receptor i alpha subunit gene
EP0854186A3 (en) Staphylococcus aureus cell division gene DivIB
WO2001027312A3 (en) Drug target isogenes: polymorphisms in the m1 muscarinic acetylcholine receptor gene
WO1999054446A3 (en) Human nucleic acid sequences which are overexpressed in normal pancreas tissue
AU2001213316A8 (en) Drug target isogenes: polymorphisms in the 5-hydroxytryptamine (serotonin) receptor 1d gene
WO2004018696A3 (en) Method for determining the allelic state of the 5'-end of the $g(a)s1-casein gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 593773

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000909076

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000909076

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09889491

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2000909076

Country of ref document: EP